Parikh, S <br/><br/>
Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa.  [electronic resource] 

 -  Clinical pharmacology and therapeutics  Aug 2007 
 - 197-203 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural 
<br/><br/><label>ISSN: </label>0009-9236 
<br/><br/><label>Standard No.: </label>10.1038/sj.clpt.6100122  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Alkynes<br/>Amodiaquine--analogs & derivatives<br/>Antimalarials--metabolism<br/>Aryl Hydrocarbon Hydroxylases--genetics<br/>Benzoxazines--metabolism<br/>Burkina Faso<br/>Chromatography, High Pressure Liquid<br/>Cyclopropanes<br/>Cytochrome P-450 CYP2C8<br/>Dose-Response Relationship, Drug<br/>Drug Interactions<br/>Enzyme Inhibitors--metabolism<br/>Genotype<br/>HIV Protease Inhibitors--metabolism<br/>Humans<br/>Lopinavir<br/>Malaria, Falciparum--drug therapy<br/>Models, Biological<br/>Polymorphism, Genetic<br/>Pyridines--metabolism<br/>Pyrimidinones--metabolism<br/>Pyrones--metabolism<br/>Reverse Transcriptase Inhibitors--metabolism<br/>Saquinavir--metabolism<br/>Spectrophotometry, Ultraviolet<br/>Sulfonamides<br/>Treatment Outcome<br/>Trimethoprim--metabolism